Daiichi Sankyo Company

Cuorips Inc. is a medical care company based in Chuo, Japan, with an additional office in Osaka. Founded in 2017, it focuses on the research, development, and commercialization of iPS cell-derived cardiomyocyte sheets and various cell therapeutic products. The company offers manufacturing and sales of cellular and tissue-based products, along with contract development and manufacturing services. Cuorips aims to advance medical treatments through innovation in cell processing and therapeutic applications.

Cuorips Inc. is a medical care company based in Chuo, Japan, with an additional office in Osaka. Founded in 2017, it focuses on the research, development, and commercialization of iPS cell-derived cardiomyocyte sheets and various cell therapeutic products. The company offers manufacturing and sales of cellular and tissue-based products, along with contract development and manufacturing services. Cuorips aims to advance medical treatments through innovation in cell processing and therapeutic applications.

Im Co.,Ltd. manufactures and sells cosmetics and over-the-counter drugs. The company offers skin care products, including moisturizing lotions and creams, make up removers, face washes, makeup primers with sun protection, and lip moisturizing treatments; and beauty supplements.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Orphan Disease Treatment Institute develops a treatment for Duchenne muscular dystrophy.

Coherus Biosciences is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of biologic therapeutics, with a strong emphasis on oncology and inflammatory diseases. The company is actively engaged in research and development, focusing on process science, analytical characterization, and protein production. Coherus's portfolio includes FDA-approved products such as UDENYCA, a biosimilar of Neulasta, and it plans to launch YUSIMRY, a biosimilar of Humira, in the United States. Additionally, the company is advancing a pipeline of biosimilar candidates across areas such as immunology and ophthalmology, as well as anti-tumor necrosis factor treatments. With a commitment to building an immuno-oncology franchise, Coherus aims to leverage its diversified portfolio to generate revenue and enhance patient access to biologic therapies.

Plexxikon, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule pharmaceuticals aimed at treating various human diseases. The company has developed several products, including PLX204 for diabetes and PLX4032 for melanoma and colorectal cancer. Additionally, it is advancing PLX5568 kinase inhibitors for conditions such as pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. Plexxikon's research encompasses a diverse portfolio of clinical and preclinical programs across multiple therapeutic areas, including metabolic diseases like obesity, oncology targeting osteolytic metastatic disease, and central nervous system disorders such as multiple sclerosis. The company is also exploring treatments for inflammation-related conditions and cardiovascular diseases.

Ranbaxy Laboratories Limited is a pharmaceutical company established in 1961, specializing in the production of quality and affordable generic medicines. The company operates in 49 countries with manufacturing facilities in 11 countries, serving customers across approximately 125 countries. Ranbaxy's extensive product portfolio includes around 5,000 stock-keeping units (SKUs) that cover a wide range of therapeutic areas for both chronic and acute conditions. The company focuses on value-added formulations and has developed several Novel Drug Delivery Systems (NDDS) aimed at enhancing drug efficacy, particularly in oral controlled-release products. Additionally, Ranbaxy engages in New Drug Discovery Research (NDDR) targeting various therapeutic segments, including infectious diseases, metabolic diseases, and oncology. The company has several ongoing research programs and has established collaborations with academic institutions to explore novel pharmaceutical agents. Notably, Ranbaxy formed a strategic alliance with Daiichi Sankyo in 2008 to strengthen its position in the generic pharmaceutical market and has entered into agreements for products such as Neuronox, a botulinum toxin for cosmetic use.

U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich. Since May 2008 U3 Pharma belongs to DAIICHI Sankyo Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and no. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.

SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, founded in 2005. It specializes in the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily focusing on oncology and hematology. The company develops various anti-cancer agents, including Treakisym, an established treatment for non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, which is currently undergoing Phase III clinical trials for relapsed/refractory diffuse large B-cell lymphoma. Additionally, SymBio is advancing several formulations, such as SyB L-1701—a ready-to-dilute formulation—and SyB L-1702, a rapid infusion formulation. Rigosertib, an oral preparation under development, is in Phase I clinical trials for solid tumors. SymBio is also working on SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes, as well as SyB V-1901, an antiviral drug aimed at treating infectious diseases, and has operations across Japan, South Korea, China, Hong Kong, Taiwan, and Singapore.